Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

RSS icon
money business cash flow dollar

AstraZeneca spends up to $1.9B for new heart disease drug

Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met. 

Ultrafast/high frame rate myocardial contrast echocardiography

Ultrafast myocardial contrast echocardiography shows early potential to evaluate CAD

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Do cancer treatments increase a patient's risk of cardiovascular disease?

Older cancer survivors appear to face higher risks of stroke, heart attack and heart failure. Early screening and preventative measures can help.

Left, coronary CT angiography of a vessel showing plaque heavy calcium burden. Right, image showing color code of various types of plaque morphology showing the complexity of these lesions. The right image was processed using the FDA cleared, AI-enabled plaque assessment from Elucid.

FDA clears new software for AI-powered CCTA assessments

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

Cardiac PET on the rise among U.S. cardiologists

SPECT is still the most common modality used to evaluate CAD patients, but cardiac PET is gaining more and more momentum.

robot reviewing heart data

Viz.ai partners with Cleerly in the name of AI-based CCTA evaluations

The new partnership is focused on getting advanced AI algorithms into the hands of cardiologists.

Heart attack patients see no benefits from stopping long-term beta-blocker therapy

Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.

Cardiac CT outperforms stress tests when screening liver transplant candidates for CAD

Heart issues are the No. 1 cause of death for liver transplant patients. Screening patients for signs of CAD is one way care teams can help keep such complications to a minimum. 

Displaying 25 - 32 of 567
Design by Adaptive Theme